

against use in case of nausea, vomiting, abdominal pains, or other symptoms of appendicitis, and a warning that frequent or continued use may cause a dependency upon laxatives to move the bowels.

DISPOSITION: 11-17-55. Default—destruction.

**4930. Devine's Zina-Ray oil, Devine's Na-Zol ointment, and Devine's inhaler.**  
(F. D. C. No. 37787. S. Nos. 14-317/8 M.)

QUANTITY: 210 2-dram vials, 393 1-oz. btls., 330 3-oz. btls., and 70 8-oz. btls. of *Devine's Zina-Ray oil*; 253 1-oz. jars of *Devine's Na-Zol ointment*; and 2,873 *Devine's inhalers*; also 1  $\frac{1}{8}$ -oz. btl. of cough syrup made with *Devine's Zina-Ray oil*; 1 1-oz. vial containing menthol; 1 1-oz. vial containing gum camphor; 1 1-oz. vial containing eucalyptus oil; 1 plaster plaque model of cross-section of the human head; 1 box with outline of cross section of the human head showing air passages and sinuses; one section of arthritic human vertebrae; and one cut-away demonstration of human skull, at St. Louis, Mo., in possession of Howard Dean, demonstrator for Devine's Remedies, Inc., of Chicago, Ill.

SHIPPED: 1-30-54 and 1-12-55, from Chicago, Ill.

RESULTS OF INVESTIGATION: Howard Dean, in the course of a sales talk, recommended the *Devine's Zina-Ray oil* and *Devine's Na-Zol ointment* for use in the treatment of the diseases and conditions described below.

Examination disclosed that the oil and ointment had the odor of eucalyptus, camphor, and menthol. The inhaler was intended for use with the oil.

LIBELED: 2-14-55, E. Dist. Mo.

CHARGE: 502 (f) (1)—the labeling of *Devine's Zina-Ray oil* and of *Devine's Na-Zol ointment*, while held for sale, failed to bear directions for use in the treatment of the conditions for which such articles were intended, namely, (oil) headache, hay fever, rose fever, sore throat, tonsillitis, bronchitis, asthma, infected sinuses, soft flabby gums, arthritis, rheumatism, swollen, sore, stiff joints, and (ointment) sore throat.

DISPOSITION: 10-5-55. Consent—claimed by Devine's Remedies, Inc. A placard entitled "Ethmoid Labyrinth" and the above-mentioned box, with its contents, were delivered to the Food and Drug Administration. The above-mentioned drugs, inhalers, and plastic cut-away model of the human head, together with leaflets entitled "Pain Sufferers," were released to the claimant and shipped to its place of business at Chicago, Ill.

**4931. Uranium ore.** (F. D. C. No. 38262. S. No. 21-050 M.)

QUANTITY: 275 pads packed with *ground uranium ore* and 1,000 lbs. of *loose uranium ore* at Gordon, Nebr., in possession of Mrs. Peggy Bartow, t/a Uranium Center.

SHIPPED: During July 1954, from Pacho, Ariz.

RESULTS OF INVESTIGATION: The *uranium ore* was shipped in bulk, and, after receipt by the consignee, a portion was packed into the pads. The *loose uranium ore* was contained in the backs and seats of full length benches and in the ceiling of a room designated "the sitting room," located in the building housing the Uranium Center.

The patient either sat or reclined on the uranium padded bench while undergoing the "treatment" provided by the purported radioactivity of the ore. The loose pads were provided the patient for placing over affected portions of the body while he was being "treated" in the sitting room.

The ore was found to possess small radioactivity. The sale of the pads and ore was promoted by sales presentations made by Mrs. Bartow and by a newspaper advertisement printed on Mrs. Bartow's instructions.

**LIBELED:** 8-3-55, Dist. Nebr.

**CHARGE:** 502 (f) (1)—the labeling of the ore and pads, while held for sale, failed to bear adequate directions for use in the treatment of arthritis, rheumatism, sinus conditions, and hemorrhoids, which were the conditions for which the articles were intended and for which they were offered in the above-mentioned advertisement and sales presentations.

**DISPOSITION:** 9-8-55. Default—destruction.

**DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM  
OFFICIAL OR OWN STANDARDS**

**4932. Sulfadiazine tablets.** (F. D. C. No. 33782. S. No. 6-556 L.)

**INFORMATION FILED:** 8-16-54, E. Dist. N. Y., against Robin Pharmacal Corp., Brooklyn, N. Y., and Sidney Rich, president.

**SHIPPED:** 5-5-52, from New York to Massachusetts.

**LABEL IN PART:** (Btl.) "1000 Sulfadiazine Berkeley (2-Sulfanilamidopyrimidine) Compressed Tablets (Scored) 0.5 Gm. (7.7 Grains)."

**CHARGE:** 501 (b)—the strength of the tablets, when shipped, differed from the standard set forth in the United States Pharmacopeia for sulfadiazine tablets since the tablets contained less than 95 percent of the declared amount of sulfadiazine, the minimum permitted by the standard.

**PLEA:** Guilty.

**DISPOSITION:** 4-24-56. Corporation and individual each fined \$1,000. Individual sentenced to imprisonment for 1 year; prison sentence suspended and individual placed on probation for 3 years.

**4933. Vitamin Spheroids.** (F. D. C. No. 38131. S. No. 2-573 M.)

**INFORMATION FILED:** 8-1-55, E. Dist. Mo., against Keith-Victor Pharmacal Co., a corporation, St. Louis, Mo.

**SHIPPED:** 12-3-54, from Missouri to Maryland.

**LABEL IN PART:** (Pkg.) "Sugar Coated Red Oval Nine Vitamin Spheroids Each Spheroid Contains: Vitamin B<sub>6</sub> Source Pyridoxine Hydrochloride Content 0.25 Mg."

**CHARGE:** 501 (c)—the strength of the article, when shipped, differed from that which it was represented to possess, in that each spheroid of the article was represented to contain 0.25 milligram of pyridoxine hydrochloride (vitamin B<sub>6</sub>), whereas each spheroid contained less than .05 milligram of pyridoxine hydrochloride.

**PLEA:** Nolo contendere.

**DISPOSITION:** 8-22-55. \$500 fine, plus costs.

**4934. Amobarbital sodium.** (F. D. C. No. 38266. S. No. 17-585 M.)

**QUANTITY:** 66 vials at Lawrenceville, Va.

**SHIPPED:** 4-22-55, from Philadelphia, Pa., by Addison Laboratories.

**LABEL IN PART:** (Vial) "Amobarbital Sodium 7½ gr. Sterile — Intravenous \* \* \* No. 6773."